Idiopathic Pulmonary Fibrosis Epidemiology Summary

• Idiopathic pulmonary fibrosis is a chronic, progressive fibrosing interstitial lung disease characterized by irreversible scarring of the lung parenchyma, leading to declining pulmonary function and premature mortality.
• Epidemiological studies indicate that IPF is one of the most common forms of idiopathic interstitial pneumonia, with prevalence varying across regions due to differences in demographics, disease recognition, and diagnostic practices.
• IPF prevalence increases markedly with age and is generally higher among men.
• cent US claims analysis estimated crude prevalence at 46.3–88.9 per 100,000 persons.
•  and sex-adjusted prevalence ranged from 34.4–67.1 per 100,000 persons.
• The pathophysiology of IPF is multifactorial, involving repetitive alveolar epithelial injury, aberrant wound-healing responses, fibroblast activation, and excessive extracellular matrix deposition that ultimately result in progressive lung fibrosis.
• The growing burden of IPF is attributed to multiple factors, including population aging, cumulative environmental and occupational exposures, smoking history, genetic susceptibility, and improved recognition of fibrotic interstitial lung diseases. Additionally, progressive fibrosis, declining lung function, and the high risk of respiratory failure contribute substantially to disease burden and complicate long-term disease management.
• Additional risk factors include cigarette smoking, environmental and occupational exposures, genetic predisposition, gastroesophageal reflux disease, and advancing age, all of which may contribute to disease susceptibility and progression.
• Growing understanding of the molecular mechanisms underlying fibrosis has highlighted the complex interplay between epithelial injury, dysregulated tissue repair, and progressive lung remodeling in the development of IPF.
• Increasing awareness among healthcare professionals, broader utilization of high-resolution computed tomography, and refinements in diagnostic criteria are expected to drive disease identification and healthcare resource utilization associated with IPF during the forecast period.

DelveInsight’s “Idiopathic Pulmonary Fibrosis Epidemiology Forecast – 2036’ report delivers an in-depth understanding of IPF  historical and forecasted epidemiology trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The IPF epidemiology report provides a comprehensive analysis of prevalent cases, capturing the number of patients across the 7MM. It includes detailed segmentation by gender and severity along with regional distribution. The report evaluates historical and forecasted prevalence trends (2026–2036), highlighting variations in disease occurrence and diagnosis patterns, and offering insights into the evolving burden of newly diagnosed IPF cases.

Idiopathic Pulmonary Fibrosis Disease Understanding

Idiopathic Pulmonary Fibrosis Overview and Diagnosis

IPF is a chronic, progressive, and ultimately fatal interstitial lung disease characterized by irreversible scarring of the lung parenchyma, resulting in a gradual decline in pulmonary function. The disease is defined by a histopathological and radiological pattern of usual interstitial pneumonia (UIP) and primarily affects older adults. Although the exact cause remains unknown, IPF is believed to arise from repeated microinjury to the alveolar epithelium in genetically susceptible individuals, leading to aberrant wound-healing responses, excessive fibroblast activation, and progressive extracellular matrix deposition. Patients typically present with exertional dyspnea, persistent dry cough, reduced exercise tolerance, and worsening respiratory impairment, which contribute substantially to morbidity and mortality.

Idiopathic Pulmonary Fibrosis Diagnosis

The diagnosis of IPF requires a comprehensive clinical evaluation aimed at excluding known causes of interstitial lung disease and identifying a UIP pattern on high-resolution computed tomography (HRCT) or lung histopathology when necessary. Diagnostic assessment typically includes detailed medical history, physical examination, pulmonary function testing, HRCT imaging, serologic testing to exclude connective tissue disease, and multidisciplinary discussion involving pulmonologists, radiologists, and pathologists. Because disease presentation may overlap with other fibrotic interstitial lung diseases, accurate and timely diagnosis is essential for disease characterization, prognostic assessment, and appropriate patient management.

Further details related to country-based variations are provided in the report...

Recent Development

In Sep 2026, Insilico Medicine dosed the first patient in "Genesis IPF-3," the world's first Phase III clinical trial for an innovative drug generated and optimized using generative artificial intelligence, targeting idiopathic pulmonary fibrosis.

In Sep 2026, Brainomix and Endeavor BioMedicines presented quantitative image analysis results from the Phase 2a trial of ENV-101 in idiopathic pulmonary fibrosis (IPF) at the ERS Congress. Brainomix’s AI-powered e-CT software demonstrated that ENV-101 treatment reduced lung tissue fibrosis progression and stabilized lung volume metrics over 12 weeks, providing objective imaging proof-of-concept for the novel Hedgehog pathway inhibitor.

Idiopathic Pulmonary Fibrosis Epidemiology

Key Findings from IPF Epidemiological Analysis and Forecast

• According to published epidemiological studies, IPF is a rare but increasingly recognized chronic fibrosis interstitial lung disease, with prevalence and incidence rising with age and occurring more frequently in men than women. The prevalence of IPF in the US is approximately 58.7 per 100,000 persons based on a nationwide database analysis of US adults over 50 years old.
• Amongst EU4, the prevalence of IPF in Spain is estimated at 21.5 cases per 100,000 inhabitants based on a population registry study, while the annual prevalence of IPF in Italy was estimated at 25.6 per 100,000 using ICD9-CM code.
• The prevalence of IPF in Japan is 27 per 100,000 population based on a nationwide claims database analysis, with an earlier epidemiological survey (2003–2007) indicating 10.0 per 100,000 population.
• Major factors contributing to regional differences in the prevalence and burden of IPF across the 7MM include variations in demographic characteristics, smoking prevalence, environmental and occupational risk factors, and disease recognition. The epidemiology of IPF is expected to evolve during the forecast period (2026–2036), supported by an aging population, improved diagnosis of interstitial lung diseases, increasing awareness among healthcare professionals, and continued refinement of diagnostic criteria.

Further details are provided in the report...

Industry Experts and Physician Views for Idiopathic Pulmonary Fibrosis

To keep up with IPF epidemiology trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the IPF epidemiology, prevalence trends, regional distribution, patient demographics, diagnostic rates, and real-world disease burden patterns in IPF, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 10+ KOLs to gather insights at country level. Centers such as the Memorial Sloan Kettering Cancer Center, University of California San Francisco, State University of New York Upstate Medical University, etc. were contacted.

Their opinion helps understand and validate IPF epidemiological trends, highlight key gaps in diagnosis and disease burden, provide deeper epidemiological context, and support strategic decisions for patient identification and disease monitoring in IPF.

Scope of the Report

• The report covers a segment of key epidemiological highlights, an executive summary, and a descriptive overview of IPF, including its causes, risk factors, and factors influencing disease occurrence.
• Comprehensive insights are provided into prevalence trends and forecasts, along with the future growth potential of prevalence rates and evolving patterns of disease detection across the 7MM.
• Additionally, the report includes detailed segmentation of prevalent cases by gender and severity offering a granular view of the epidemiological landscape.
• A thorough assessment of historical and forecasted prevalence data, along with underlying assumptions and methodology, is included, providing a clear understanding of disease burden across the 7MM.
• The report provides strategic insights by highlighting trends in prevalence, diagnostic gaps, and regional variations, supported by expert opinions and epidemiological analysis to better understand and project the IPF disease burden.

Report Insights

• IPF prevalence forecast, epidemiological burden, segmentation, trends, and opportunity assessment.

Report Key Strengths

• Epidemiology-based (EPI - based) bottom-up forecasting
• Artificial Intelligence (AI) - enabled epidemiology research report
• 11-year forecast
• IPF epidemiological outlook (North America, Europe, Asia-Pacific)
• IPF Burden trends (by geography)

Report Assessment

• Idiopathic Pulmonary Fibrosis Diagnostic Trends
• Idiopathic Pulmonary Fibrosis Epidemiological Gaps
• Idiopathic Pulmonary Fibrosis Development Trends
• Idiopathic Pulmonary Fibrosis Emerging Research Focus
• Idiopathic Pulmonary Fibrosis Disease Burden Attractiveness
• Idiopathic Pulmonary Fibrosis Qualitative Epidemiological Insights

Explore the Idiopathic Pulmonary Fibrosis Market Forecast to uncover emerging therapies, pipeline developments, competitive dynamics, and growth opportunities shaping the future landscape.

FAQs

• What was the IPF prevalent patient population and distribution (%) in 2025, and how will it evolve by 2036? What factors are driving these trends?
• What are the anticipated variations in prevalence and diagnosis rates across different geographies?
• What will be the future diagnosis and epidemiological trends of IPF?
• What are the disease risks, burden, and key epidemiological gaps in IPF? What are the growth opportunities based on the patient population across the 7MM?
• How will changes in prevalence and diagnosis impact the overall epidemiological landscape?
• What are the current diagnosis practices and epidemiology trends of IPF in the US, Europe, UK, and Japan?

Reasons to Buy

• The report will help in developing strategies by understanding the latest trends and changing epidemiology of IPF.
• Bottom-up forecasting builds from the prevalent patient population, delivering a robust, data-driven epidemiological approach.
• Insights on patient burden/prevalence, evolution in diagnosis, and factors contributing to changes in disease epidemiology during the forecast years.
• Understand the epidemiological opportunities across varying geographies and growth potential over the coming years.
• Identifying key trends in disease prevalence will help anticipate shifts in the epidemiological landscape.
• Detailed analysis and segmentation of prevalent cases to provide visibility around high-burden patient groups.
• To understand KOLs’ perspectives on diagnosis challenges and gaps in disease identification.
• Detailed insights on epidemiological unmet needs to support improved disease tracking and diagnosis strategies.
• This Artificial Intelligence (AI)-enabled report summarizes complex epidemiological datasets into clear, actionable insights for stakeholders, investors, and healthcare providers.